微生物组诊断市场- 副产品（试剂盒和试剂、仪器）、技术（16S rRNA 定序、鸟枪式宏基因组学）、样本（粪便样本、唾液样本）、应用（疾病诊断）、最终用途- 全球预测（2024年- 2032 年）

在新一代定序 NGS 等定序技术的进步以及慢性病发病率上升的推动下，2024 年至 2032 年全球微生物组诊断市场规模将以 13.4% 的复合年增长率成长。这些技术可以对微生物群落进行详细分析，从而提供对疾病机制和个人化治疗策略的见解。

随着医疗保健产业越来越关注预防和个人化医疗，微生物组诊断在了解疾病途径和优化患者护理方面发挥着至关重要的作用，推动了研究和临床应用的成长。例如，2024 年 2 月，ALS 推出了肠道微生物组定序服务，为全球研究人员提供全面、可发表的资料，以获得对人类和动物肠道微生物组的深刻见解。

微生物组诊断产业根据产品、技术、样本、应用、最终用途和地区进行划分。

从技术角度来看，鸟枪法宏基因组学领域将在 2032 年之前实现显着的复合年增长率，这要归功于其直接从样本中分析微生物 DNA 的综合方法。该方法提供了对微生物群落的详细了解，有助于精确的疾病诊断和治疗策略。随着定序技术和生物资讯学的进步，鸟枪法宏基因组学进一步使人们能够更深入地了解微生物组的组成和功能

就样本而言，唾液样本领域的微生物组诊断市场规模将在2032年增长。它们还提供有关口腔和全身健康的见解，以支持个人化医疗和健康评估。不断涌现的研究也正在扩大口腔微生物组在各种疾病中的作用，包括代谢紊乱和口腔癌。此外，基于唾液的诊断因其在推进微生物组研究和临床应用方面的功效和可及性而得到越来越多的认可。

在医疗保健支出增加和个人化医疗意识不断提高的推动下，亚太地区微生物组诊断市场将在 2024 年至 2032 年间实现显着的复合年增长率。随着研究计划的扩大和先进诊断技术的采用，该地区的多样化人口正在为了解微生物组变化做出贡献。随着各国政府优先考虑医疗基础设施和监管框架，亚太地区将成为推动微生物组诊断的重要贡献者。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

• 产业生态系统分析
• 产业影响力
  • 成长动力
  • 慢性病盛行率增加
  • 个人化医疗需求不断成长
  • 人们越来越认识到人类微生物组的重要性
  • 微生物组研究的经费和投资不断增加
  • 产业陷阱与挑战
  • 与微生物组测试相关的高成本
• 成长潜力分析
• 监管环境
• 技术景观
• 波特的分析
• PESTEL分析

第 4 章：竞争格局

• 介绍
• 公司市占率分析
• 竞争定位矩阵
• 战略展望矩阵

第 5 章：市场估计与预测：按产品分类，2021 - 2032 年

• 主要趋势
• 试剂盒和试剂
• 仪器

第 6 章：市场估计与预测：按技术分类，2021 - 2032 年

• 主要趋势
• 16S rRNA测序
• 鸟枪法宏基因体学
• 宏转录组学
• 其他技术

第 7 章：市场估计与预测：按样本，2021 - 2032 年

• 主要趋势
• 粪便样本
• 唾液样本
• 皮肤样本
• 其他样品

第 8 章：市场估计与预测：按应用分类，2021 - 2032

• 主要趋势
• 疾病诊断
  • 胃肠道疾病
  • 代谢紊乱
  • 其他疾病诊断
• 研究应用

第 9 章：市场估计与预测：依最终用途，2021 - 2032 年

• 主要趋势
• 医院
• 学术及研究机构
• 製药和生物技术公司

第 10 章：市场估计与预测：按地区，2021 - 2032

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 欧洲其他地区
• 亚太地区
  • 日本
  • 中国
  • 印度
  • 澳洲
  • 韩国
  • 亚太地区其他地区
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 拉丁美洲其他地区
• 中东和非洲
  • 沙乌地阿拉伯
  • 南非
  • 阿联酋
  • 中东和非洲其他地区

第 11 章：公司简介

• Becton, Dickinson, and Company
• Biome Technologies plc
• Genetic Analysis AS
• Illumina, Inc.
• Microba Life Sciences Limited
• Micronoma, Inc.
• OraSure Technologies, Inc.
• Oxford Nanopore Technologies plc
• Quantbiome, Inc.
• ViennaLab Diagnostics GmbH

Global Microbiome Diagnostics Market size will expand at 13.4% CAGR from 2024 to 2032, fueled by advancements in sequencing technologies, such as next-generation sequencing NGS, coupled with the rising incidence of chronic diseases. These technologies are enabling detailed analysis of microbial communities for offering insights into disease mechanisms and personalized treatment strategies.

With the healthcare sector increasingly focusing on preventive and personalized medicine, microbiome diagnostics are playing a crucial role in understanding disease pathways and optimizing patient care, driving growth in both research and clinical applications. For instance, in February 2024, ALS launched the Gut Microbiome Sequencing service for providing global researchers with comprehensive, publication-ready data to gain profound insights into the human and animal gut microbiome.

The microbiome diagnostics industry is divided based on product, technology, sample, application, end-use, and region.

By technology, the shotgun metagenomics segment will secure a noteworthy CAGR through 2032, attributed to its comprehensive approach in analyzing microbial DNA directly from samples. This method offers detailed insights into microbial communities for aiding in precise disease diagnosis and therapeutic strategies. With advancements in sequencing technologies and bioinformatics, shotgun metagenomics are further enabling a deeper understanding of microbiome composition and function

In terms of sample, the microbiome diagnostics market size from the saliva samples segment will grow by 2032. By offering non-invasive collection and diverse microbial representation, saliva samples facilitate convenient and repeated testing. They also provide insights into oral and systemic health for supporting personalized medicine and wellness assessments. Rising research is also expanding the role in of oral microbiome in various diseases, including metabolic disorders and oral cancers. Moreover, saliva-based diagnostics are increasingly recognized for their efficacy and accessibility in advancing microbiome research and clinical applications.

Asia Pacific microbiome diagnostics market will record a remarkable CAGR between 2024 and 2032, propelled by the increasing healthcare expenditure and the rising awareness of personalized medicine. With expanding research initiatives and adoption of advanced diagnostic technologies, the diverse population of the region is contributing to the understanding of microbiome variations. As governments prioritize healthcare infrastructure and regulatory frameworks, Asia Pacific will emerge as a significant contributor to advancing microbiome diagnostics.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
  • 3.2.2 Increasing prevalence of chronic diseases
  • 3.2.3 Rising demand of personalized medicine
  • 3.2.4 Growing awareness about importance of human microbiomes
  • 3.2.5 Rising funding and investments in microbiome research
  • 3.2.6 Industry pitfalls & challenges
  • 3.2.7 High cost associated with microbiome testing
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Technological landscape
• 3.6 Porter's analysis
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Competitive positioning matrix
• 4.4 Strategy outlook matrix

Chapter 5 Market Estimates and Forecast, By Product, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Kits and reagents
• 5.3 Instruments

Chapter 6 Market Estimates and Forecast, By Technology, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 16S rRNA sequencing
• 6.3 Shotgun metagenomics
• 6.4 Metatranscriptomics
• 6.5 Other technologies

Chapter 7 Market Estimates and Forecast, By Sample, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Fecal samples
• 7.3 Saliva samples
• 7.4 Skin samples
• 7.5 Other samples

Chapter 8 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Disease diagnostic
  • 8.2.1 Gastrointestinal disorders
  • 8.2.2 Metabolic disorders
  • 8.2.3 Other disease diagnostics
• 8.3 Research applications

Chapter 9 Market Estimates and Forecast, By End-Use, 2021 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 Hospitals
• 9.3 Academic and research institutes
• 9.4 Pharmaceuticals and biotechnology companies

Chapter 10 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 10.1 Key trends
• 10.2 North America
  • 10.2.1 U.S.
  • 10.2.2 Canada
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 France
  • 10.3.4 Spain
  • 10.3.5 Italy
  • 10.3.6 Rest of Europe
• 10.4 Asia Pacific
  • 10.4.1 Japan
  • 10.4.2 China
  • 10.4.3 India
  • 10.4.4 Australia
  • 10.4.5 South Korea
  • 10.4.6 Rest of Asia Pacific
• 10.5 Latin America
  • 10.5.1 Brazil
  • 10.5.2 Mexico
  • 10.5.3 Argentina
  • 10.5.4 Rest of Latin America
• 10.6 Middle East and Africa
  • 10.6.1 Saudi Arabia
  • 10.6.2 South Africa
  • 10.6.3 UAE
  • 10.6.4 Rest of Middle East and Africa

Chapter 11 Company Profiles

• 11.1 Becton, Dickinson, and Company
• 11.2 Biome Technologies plc
• 11.3 Genetic Analysis AS
• 11.4 Illumina, Inc.
• 11.5 Microba Life Sciences Limited
• 11.6 Micronoma, Inc.
• 11.7 OraSure Technologies, Inc.
• 11.8 Oxford Nanopore Technologies plc
• 11.9 Quantbiome, Inc.
• 11.10 ViennaLab Diagnostics GmbH